Glycyl-Glutamine: Evidence, Mechanism, Dosing & Legal Status

Glycyl-L-glutamine (Gly-Gln) is a small dipeptide with two almost-unrelated identities that peptide marketing routinely conflates: a chemically stable vehicle for delivering glutamine intravenously in clinical nutrition, and an endogenous fragment of β-endorphin that acts as a brainstem neuromodulator. Honest grading depends on keeping them apart.48

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. There is no FDA-approved glycyl-glutamine drug; parenteral glutamine-dipeptide nutrition is a hospital/ICU agent, and benchtop 'Gly-Gln' is sold as a 'research chemical, not for human consumption.' Dosing figures are reported strictly as documented in the literature and clinical-nutrition practice — not as recommendations. Consult a licensed clinician before any health decision.

What is glycyl-glutamine and how does it work?

Chemically, glycyl-L-glutamine is the dipeptide of glycine and L-glutamine: molecular formula C₇H₁₃N₃O₄, molecular weight about 203.2 g/mol, CAS 13115-71-4, catalogued as PubChem CID 123913.1 The peptide bond confers the property that defines its nutritional use: unlike free L-glutamine — which is unstable in aqueous solution, degrades on heat sterilization, and forms pyroglutamate and ammonia on storage — the dipeptide is heat-stable, highly water-soluble and storage-stable, then is rapidly hydrolyzed in plasma and tissue by ubiquitous peptidases to release free glutamine and glycine.4

The first mechanism is stable glutamine delivery. Glutamine is a conditionally essential amino acid and the principal fuel for enterocytes, lymphocytes and other rapidly dividing cells; demand outstrips supply in catabolic stress such as trauma, sepsis, surgery and chemotherapy. Because glutamine cannot be put into standard amino-acid bags, the dipeptide acts as a pro-drug carrier: infused intravenously, it is cleaved to liberate glutamine where it supports protein synthesis, gut-mucosal integrity, glutathione antioxidant synthesis and immune function.4 In a polytrauma dose-finding RCT, infused glycyl-glutamine raised and sustained plasma glutamine with negligible urinary loss of the dipeptide, glutamine or glycine — confirming efficient hydrolysis and utilization rather than renal spillage.2

The second mechanism is unrelated to nutrition. Post-translational processing of β-endorphin-(1–31) generates β-endorphin-(1–27)/(1–26) plus the C-terminal dipeptide Gly-Gln — that is, β-endorphin-(30–31).8 Gly-Gln is present in the brainstem in amounts roughly equal to the sum of those shortened β-endorphin fragments, inhibits firing of brainstem reticular neurons, and behaves as an endogenous functional antagonist of β-endorphin-(1–31) — without an identified classical opioid receptor and without blocking opioid analgesia.1011 Critically, the effects are not reproduced by equimolar free glycine plus glutamine, indicating the intact dipeptide is the active species.8 As a nutrition agent the route is intravenous only and the plasma half-life is short; the centrally active findings used intracerebroventricular dosing in rodents, which does not translate to a human therapy.

What is the evidence by indication?

The two identities sit at very different evidence grades. Below, the parenteral-nutrition indication carries genuine human data (Grade B), while every neuro/cardiometabolic claim is preclinical (Grade C) or pure marketing (Grade D).

The parenteral-nutrition evidence is the substantive part. A polytrauma dose-finding RCT randomized 9 patients across three dose arms (280, 450 and 570 mg glycyl-glutamine/kg/day, roughly 14, 21 and 28 g glutamine/day for a 70-kg adult) plus 7 controls over four days; doses at or above 450 mg/kg/day raised plasma glutamine, only the 570 mg/kg/day arm sustained it, and there were no side effects and no pathological accumulation — though the primary endpoint was metabolic, not a clinical outcome, and the sample was tiny.2 A randomized, double-blind acute-leukemia trial compared glutamine-free TPN with glycyl-glutamine-supplemented TPN (20 g glutamine) and found significantly faster neutrophil recovery after high-dose cytarabine.3 Class-level meta-analyses — largely of the alanyl-glutamine sibling — reinforce this: an abdominal-surgery meta-analysis of 9 RCTs and 373 patients showed improved nitrogen balance, reduced infectious morbidity and a hospital-stay reduction of about 3.5 days with no serious adverse effects, and a surgical-patient meta-analysis reported an even larger length-of-stay benefit for the glycyl form.45 A systematic evaluation found guideline-dosed parenteral glutamine-dipeptide associated with improved outcomes in critically ill patients.6

The important caveat is that this evidence base is heterogeneous and contested. Early ICU trials suggested mortality, infection and length-of-stay benefit, but several later RCTs — and large trials of enteral or high-dose glutamine using different formulations and populations — did not replicate benefit and even raised harm signals at supraphysiologic doses in multi-organ-failure patients.7 The net is a legitimate, internationally used adjunct with real but modest, population-dependent benefit — graded B, not A.

The preclinical neuropeptide story is intriguing but unproven in humans. In conscious rats, intracerebroventricular Gly-Gln (3–30 nmol) dose-dependently attenuated hemorrhage-induced hypotension and raised heart rate while being inactive on its own in normotensive animals, and it reversed opioid-induced respiratory depression.89 In rodents it also inhibited morphine conditioned place preference and attenuated tolerance, dependence and withdrawal without interfering with analgesia.10 No human cardiovascular or addiction trials exist. This preclinical kernel is exactly what 'cardiometabolic peptide' marketing inflates.

What doses appear in the literature, and how safe is it?

Reported strictly as information, not a protocol. The route is intravenous, always within a complete TPN or amino-acid regimen — never as a standalone bolus.2 Guideline-anchored glutamine-dipeptide dosing is roughly 0.3–0.5 g glutamine/kg/day (and no more than about 30% of total amino-acid intake), co-administered with adequate energy and protein.6 The polytrauma RCT used 280, 450 or 570 mg glycyl-glutamine/kg/day, with up to 570 mg/kg/day tolerated without renal substrate loss, and the oncology RCT used a fixed roughly 20 g glutamine/day supplemented TPN.23 Commercial dipeptide concentrate — for example the alanyl-glutamine product Dipeptiven 20% — is diluted into the carrier amino-acid solution before infusion, not given undiluted; these are hospital-pharmacy and ICU agents, not consumer reconstituted vials.13 The rodent neuropeptide studies used intracerebroventricular nanomole doses with no human CNS-delivery route.8

On safety, the agents were well tolerated in trials, with no serious adverse effects reported across the small glycyl-glutamine studies and the larger dipeptide meta-analyses, and no pathological glycine or dipeptide accumulation in the polytrauma RCT.24 The cautions are those of the glutamine load rather than the peptide itself: severe renal impairment limits clearance of nitrogenous byproducts, and hepatic impairment or hepatic encephalopathy is a concern because glutamine is metabolized to glutamate and ammonia.4 Supraphysiologic glutamine in unstable multi-organ-failure ICU patients has been associated with no benefit or possible harm in some large trials — a formulation, dose and population effect rather than a glycyl-glutamine-specific toxicity.7 Glutamine is also an avid fuel for many tumors, a legitimate theoretical oncology caution, and pregnancy and lactation are untested.3 Grey-market 'Gly-Gln' carries the usual research-chemical hazards of unverified purity and no sterility assurance.12

What is the FDA and WADA status in 2026?

There is no FDA-approved glycyl-glutamine product. More broadly, glutamine dipeptides are not FDA-approved in the United States: the marketed alanyl-glutamine product Dipeptiven (Fresenius Kabi) is registered and widely used internationally — the UK, EU, New Zealand, India and the Middle East — but has not been registered in the USA, where it has only been used as an investigational product in clinical trials.1314 No US compounding bulk-substance listing establishes glycyl-glutamine as a compoundable peptide drug, and suppliers market it as a high-purity dipeptide 'for laboratory/research use only — not for human consumption, veterinary, or medical use.'12 It is not a DEA-controlled substance.

For athletes the anti-doping picture is favorable but practically moot. Glutamine and glutamine dipeptides do not appear on the WADA 2026 Prohibited List, in force since January 1, 2026, and there is no evidence of performance enhancement.1516 Athletes remain strictly liable for supplement contamination and should verify products through GlobalDRO. Because there is no athlete performance evidence for glycyl-glutamine, its permitted status does not translate into any meaningful sport rationale.

Bottom line. Glycyl-glutamine is two molecules under one name, and honest grading separates them. As a clinical-nutrition glutamine carrier it earns Grade B — real but modest human evidence, tempered by negative later ICU trials and a tumor-fuel caution. As an endogenous β-endorphin-(30–31) neuropeptide it is Grade C, entirely animal and in-vitro with no defined receptor, and the 'metabolic / longevity peptide' positioning is Grade D marketing. Regulatory facts here are current as of June 2026 and should be re-verified for any specific jurisdiction or product.